All samples·Sample analysis
Get your own pass — $199
granted.bioAll samples
Analysis

radioligand therapy for prostate cancer

Overview
  • Dashboard
Analysis
  • What Surprised Us
  • Field Maturity
  • Funding Landscape
  • Competitive Topology
  • White Space
  • Market Context
Data
  • Projects115
  • Clinical Trials500
  • Patents29
  • Publications646
  • Organizations52
  • Researchers125
Reference
  • Methodology
Back
radioligand therapy for prostate cancerOrganizationsUNIVERSITY OF VIRGINIA

UNIVERSITY OF VIRGINIA

Projects attributed to UNIVERSITY OF VIRGINIA within this analysis sample.

In This Analysis
Projects
2
NIH Funding
$2.0M
Projects(2)
ProjectPICategoryFunding
Targeting tumor-specific epitope for imaging and therapy for mesothelioma
5R01CA288612-02
HE, JIANGTherapeutics$1.3M
Small Molecule ERG Inhibitors for Prostate Cancer
5R01CA282472-02
BUSHWELLER, JOHN HACKETTTherapeutics$664K
See UNIVERSITY OF VIRGINIA’s full platform profile
Cross-source view across the entire granted.bio dataset — projects, trials, patents, and publications spanning every topic, not just this analysis.